The U.S. healthcare system is currently navigating unprecedented challenges as the CDC faces a leadership crisis. This turmoil has intensified debates over Ivermectin access, its affordability, and its preventive medicine role. Americans are increasingly questioning institutional guidance while exploring preventive care options, highlighting the tension between public health directives and...

In 2025, the United States stands at a crossroads between evidence-based medicine and persistent misinformation. On one side, groundbreaking weight-loss drugs such as GLP-1 agonists are revolutionizing obesity treatment, improving cardiovascular health, and reshaping healthcare costs. On the other, Ivermectin misinformation—often tied to old pandemic...